Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.53 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6914288 | 1.00 | POLB (0.62) | POLBLMNAPDE3ADNMT1CACNA1F | |
| Phosphoric Acid SCHEMBL1970387 | 0.95 | POLB (0.67) | POLBLMNAPDE3ADNMT1CACNA1F | |
| Doxecitine SCHEMBL193815 | 0.90 | DNMT1 (0.66) | POLBLMNAPDE3ADNMT1CACNA1F | |
| Doxecitine SCHEMBL23178 | 0.90 | DNMT1 (0.66) | POLBLMNAPDE3ADNMT1CACNA1F | |
| Doxecitine SCHEMBL15832461 | 0.90 | DNMT1 (0.66) | POLBLMNAPDE3ADNMT1CACNA1F | |
| Doxecitine SCHEMBL23346798 | 0.90 | DNMT1 (0.66) | POLBLMNAPDE3ADNMT1CACNA1F | |
| Doxecitine SCHEMBL13700553 | 0.90 | DNMT1 (0.66) | POLBLMNAPDE3ADNMT1CACNA1F | |
| Doxecitine SCHEMBL10238960 | 0.90 | DNMT1 (0.66) | POLBLMNAPDE3ADNMT1CACNA1F | |
| Doxecitine SCHEMBL887491 | 0.90 | DNMT1 (0.66) | POLBLMNAPDE3ADNMT1CACNA1F | |
| SCHEMBL3693586 | 0.90 | POLB (0.62) | POLBLMNAPDE3ADNMT1CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056970-A1 | MAMMALIAN CELL CULTURE ADDITIVES | VIROCELL BIOLOGICS LTD (GB) | 2025-03-20 | — | — | WO | claimed |
| US-20200016182-A1 | STAT5a AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES | NIH - DEITR | 2020-01-16 | — | — | US | claimed |
| US-10166251-B2 | STAT5a and its functional tumor suppressor analogs for treatment of malignancies expressing NPM/ALK and other oncogenic kinases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2019-01-01 | — | — | US | claimed |
| US-20170106008-A1 | STAT5a AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-04-20 | — | — | US | claimed |
| US-9486469-B2 | STAT5a and its functional tumor suppressor analogs for treatment of malignancies expressing NPM/ALK and other oncogenic kinases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-11-08 | — | — | US | claimed |
| US-20130165502-A1 | Diagnostic, Prognostic and Therapeutic Uses of miRs in Adaptive Pathways and Disease Pathways | THE OHIO STATE UNIVERSITY (US) | 2013-06-27 | — | — | US | claimed |
| US-20110086043-A1 | STAT5a AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-14 | — | — | US | claimed |
| US-20110077215-A1 | DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL) | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2011-03-31 | — | — | US | claimed |
| US-20100278937-A1 | COMPOSITIONS AND METHODS TO PREVENT AND/OR TREAT CANCER WITH PA-CARD | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2010-11-04 | — | — | US | claimed |
| WO-2010096754-A1 | COMPOSITIONS AND METHODS TO PREVENT AND/OR TREAT CANCER WITH PA -CARD | CDG THEREAPEUTICS, INC. (US) | 2010-08-26 | — | — | WO | claimed |
| WO-2009045965-A2 | STAT5A AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-04-09 | — | — | WO | claimed |
| EP-1963532-A2 | DNA METHYLATION AS A TARGET FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | University of Utah Research Foundation (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067695-A2 | DNA METHYLATION AS A TARGET FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2007-06-14 | — | — | WO | claimed |
| US-20060127896-A1 | Materials and methods for treating cancer | GOH, CHRISTOPHER H K (SG) | 2006-06-15 | — | — | US | claimed |
| WO-2004035045-A1 | USE OF SUBSTITUTED ACRYLOLYL DISTAMYCIN DERIVATIVES IN COMBINATION WITH DEMETHYLATING AGENTS, IN THE TREATMENT OF CANCER | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-29 | — | — | WO | claimed |
| US-20250223554-A1 | METHODS AND COMPOSITIONS USING RECOMBINANT DENDRITIC CELLS FOR CANCER THERAPY | RENOVARO BIOPHARMA INC. | 2025-07-10 | — | — | US | disclosed |
| WO-2025056970-A1 | MAMMALIAN CELL CULTURE ADDITIVES | VIROCELL BIOLOGICS LTD (GB) | 2025-03-20 | — | — | WO | disclosed |
| EP-0215942-A1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. | SUMMERTON JAMES | 1987-04-01 | — | — | EP | disclosed |
| WO-1986005519-A1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |
| WO-1986005518-A1 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |